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1. INTRODUCTION {#clc23358-sec-0006}
===============

Myocardial infarction (MI) is characterized by chest pain and/or dyspnea as a result of myocardial ischemia and injury. MI can be divided into ST‐segment elevation myocardial infarction (STEMI) and non‐ST elevation myocardial infarction (NSTEMI) based on electrocardiography changes. With the increasing utilization of medical therapies and reperfusion interventions, the short‐term mortality of MI has been steadily decreasing over the past decade. In‐hospital mortality is 5.5% among STEMI and 3.9% among NSTEMI.[1](#clc23358-bib-0001){ref-type="ref"} Many preexisting factors have been identified that affect the outcomes of MI, such as age, sex, prior MI,[2](#clc23358-bib-0002){ref-type="ref"} peripheral artery disease (PAD),[3](#clc23358-bib-0003){ref-type="ref"} chronic obstructive pulmonary disease (COPD),[4](#clc23358-bib-0004){ref-type="ref"} obstructive sleep apnea (OSA),[5](#clc23358-bib-0005){ref-type="ref"} chronic kidney disease (CKD),[6](#clc23358-bib-0006){ref-type="ref"} prior stroke,[7](#clc23358-bib-0007){ref-type="ref"} and traditional cardiovascular risk factors (hypertension, smoking, dyslipidemia, and diabetes).[8](#clc23358-bib-0008){ref-type="ref"} In recent years, numerous studies have shown that psychosocial factors, especially depression disorders, play an adverse role in the prognosis for MI and maybe even more significant than traditional cardiovascular risk factors.[9](#clc23358-bib-0009){ref-type="ref"}, [10](#clc23358-bib-0010){ref-type="ref"}, [11](#clc23358-bib-0011){ref-type="ref"} Although highly overlapped with depression disorders, anxiety disorders as a cardiovascular risk factor have not been studied as extensively as other psychosocial factors. Anxiety disorders are prevalent in patients with MI,[12](#clc23358-bib-0012){ref-type="ref"} and the effects of them can manifest pre‐ or post‐MI. Previous studies have shown that preexisting anxiety is an independent predictor of MI,[13](#clc23358-bib-0013){ref-type="ref"}, [14](#clc23358-bib-0014){ref-type="ref"} and post‐MI anxiety will worsen the long‐term prognosis of MI, associated with increased medical consumption, a higher incidence of cardiovascular events, and the greater out of hospital mortality.[15](#clc23358-bib-0015){ref-type="ref"}, [16](#clc23358-bib-0016){ref-type="ref"}, [17](#clc23358-bib-0017){ref-type="ref"} Some studies focused on the effect of preexisting anxiety on the long‐term prognosis of post‐MI. For instance, Smeijers et al found that preexisting anxiety will increase the 10‐year mortality risk among MI patients.[18](#clc23358-bib-0018){ref-type="ref"} However, a few studies that focus on the short‐term outcomes for patients with preexisting anxiety at the time of AMI, especially in‐hospital outcomes which contributes the most of mortality in MI patients. Interestingly, a recent study by Pino et al demonstrated that patients with anxiety and/or depression at the time of STEMI paradoxically have a better in‐hospital outcome.[19](#clc23358-bib-0019){ref-type="ref"} However, the study did not distinguish between anxiety and depression disorders, and only STEMI patients were studied. Our study aims to investigate the impact of preexisting anxiety disorders on in‐hospital outcomes in both NSTEMI and STEMI patients after adjusting for other well‐established risk factors and depressive disorders.

2. METHOD {#clc23358-sec-0007}
=========

We conducted a retrospective cohort study using the National Inpatient Sample (NIS) 2016 database. The NIS is part of the Healthcare Cost and Utilization Project (HCUP) and includes administrative and demographic data involving a stratified sample of 20% (more than 7 million each year) of inpatient hospitalizations in the United States, excluding rehabilitation and long‐term care facilities.[20](#clc23358-bib-0020){ref-type="ref"} It contains the following variables: primary and secondary diagnoses, patient demographic characteristics, hospital characteristics, total charges, expected payer, discharge status, length of stay (LOS), and severity and comorbidity measures. Because of the large sample size, the NIS has been used in developing national and regional estimates. All the discharge diagnoses in the 2016 NIS database are identified by the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD‐10‐CM) Codes.

MI patients over 18 years old who were admitted to hospital from 1 January 2016 to 31 December 2016 were selected by the ICD‐10‐CM codes. Patients with missing information on discharge status were excluded. Eligible patients with MI were further grouped based on whether they had anxiety disorders or not. The selection process for the final patient sample used in this study was illustrated in Figure [1](#clc23358-fig-0001){ref-type="fig"}.

![Flow chart of the selection process for the final patient sample used in this study. Inclusion criteria were applied to the National Inpatient Sample 2016 database. All eligible patients were matched 1:1 based on propensity scoring to generate the anxiety vs nonanxiety comparison cohorts. ICD‐10‐CM code, Tenth Revision, Clinical Modification Code. MI, myocardial infarction; NSTEMI, non‐ST elevation myocardial infarction; STEMI, ST‐segment elevation myocardial infarction](CLC-43-622-g001){#clc23358-fig-0001}

Review by an institutional review board is not required for use of NIS.

3. VARIABLES {#clc23358-sec-0008}
============

The baseline data included age, sex, race, geographic location, household income, primary payer, hospital‐level characteristics, such as hospital type, region and bed size, and risk factors for adverse outcomes of MI: smoking, hypertension, hyperlipidemia, diabetes mellitus (DM), obesity, history of MI, OSA, CKD, history of stroke, PAD, COPD, and depression disorders. All the comorbidities mentioned above were extracted directly from the NIS database by the ICD‐10‐CM codes (Table [S1](#clc23358-supitem-0003){ref-type="supplementary-material"}).

4. OUTCOMES {#clc23358-sec-0009}
===========

The primary outcomes were defined as in‐hospital death, cardiac arrest, and cardiogenic shock. The secondary outcomes were LOS, total hospitalization costs, and serious in‐hospital complications: ventricular arrhythmia (VA), acute congestive heart failure (CHF), acute kidney injury (AKI), and acute respiratory failure (ARF). All the ICD‐10 codes representing the outcomes were shown in Table [S1](#clc23358-supitem-0003){ref-type="supplementary-material"}.

5. STATISTICAL ANALYSES {#clc23358-sec-0010}
=======================

Categorical variables are represented by numbers and proportions by chi‐square test. Continuous variables are presented by mean and standard deviation (SD). A propensity score‐matched analysis of the anxiety vs the nonanxiety group was performed to reduce the selection bias within the unmatched cohort.

To adjust for age, gender, race, mean household income, hospital type, hospital region, and risk factors for adverse outcome of MI, we built a multivariate logistic regression model to measure a propensity score. We conducted a nearest neighbor matching of both groups with a caliper match tolerance of 0.25 to decide the subsequent individually matched propensity score. Next, the primary and secondary outcomes between the anxiety and without anxiety groups were compared in both the unmatched and the propensity score‐compatible cohorts. Patients with MI were further divided into STEMI and NSTEMI subgroups. A propensity score‐matched analysis of the anxiety vs nonanxiety groups was performed in the STEMI and NSTEMI subgroups, respectively. Finally, the same primary outcomes (death, cardiac arrest, and cardiogenic shock) and secondary outcomes (LOS, total cost, VA, acute CHF, AKI, and ARF) between the anxiety and without anxiety groups in the subgroup were measured. The patient selection process for the subgroups was illustrated in Figures [S1](#clc23358-supitem-0001){ref-type="supplementary-material"} and [S2](#clc23358-supitem-0002){ref-type="supplementary-material"}. All statistical analyses were performed by the R statistics software. The value of *P* \< .05 was considered significant.

6. RESULTS {#clc23358-sec-0011}
==========

A total of 129 305 acute MI patients (including STEMI 35 237, 27.3% and NSTEMI 94 068, 72.7%) were identified, in which 13 112 (10.1%) had anxiety disorders (2770 in STEMI and 10 342 in NSTEMI).

In the unmatched cohort of MI, compared with the patients without anxiety, the patients with anxiety tended to be younger (65.5 ± 13.7 vs 67.2 ± 13.6, *P* \< .001), female (56.1% vs 36.0%, *P* \< .001), white (79.7% vs 70.1%, *P* \< .001), and had a higher incidence of comorbidities: smoking (29.4% vs 23.0%, *P* \< .001), hypertension (56.9% vs 53.7%, *P* \< .001), hyperlipidemia (68.0% vs 64.7%, *P* \< .001), obesity (21.0% vs 18.4%, *P* \< .001), depression (32.1% vs 5.8%, *P* \< .001), history of MI (17.9% vs 15.0%, *P* \< .001), OSA (11.7% vs 8.4%, *P* \< .001), history of stroke (11.3% vs 10.0%, *P* \< .001), PAD (13.3% vs 12.5%, *P* = .005), and COPD (26.5% vs 17.0%, *P* \< .001). Interestingly, the incidence of DM (36.4% vs 38.9%, *P* \< .001) and CKD (21.6% vs 23.7%, *P* \< .001) was less in the group with anxiety. After propensity score matching, each group consisted of 13 102 patients, although sex and race still differ between the two groups. Like the unmatched MI, the pre‐MI anxiety group was proportionately more female (56.1% vs 54.4%, *P* = .013), and white (79.7% vs 76.6%, *P* \< .001) (Table [1](#clc23358-tbl-0001){ref-type="table"}).

###### 

Baseline characteristics of patients with MI

                                                                   Unmatched cohort                   Propensity‐matched cohort                                   
  ---------------------------------------------------------------- ------------------ --------------- --------------------------- --------------- --------------- --------
  n                                                                116 193            13 112                                      13 102          13 102          
  Age, (mean \[SD\])                                               67.2 (13.6)        65.5 (13.7)     \<.001                      65.5 (13.6)     65.5 (13.7)     .966
  Sex, n (%)                                                                                          \<.001                                                      .013
  Male                                                             74 363 (64.0)      5749 (43.8)                                 5975 (45.6)     5749 (43.9)     
  Female                                                           41 775 (36.0)      7356 (56.1)                                 7123 (54.4)     7346 (56.1)     
  Unknown                                                          55 (0.0)           7 (0.1)                                     4 (0.0)         7 (0.1)         
  Race, n (%)                                                                                         \<.001                                                      \<.001
  White                                                            81 460 (70.1)      10 449 (79.7)                               10 040 (76.6)   10 440 (79.7)   
  Black                                                            13 061 (11.2)      876 (6.7)                                   1361 (10.4)     875 (6.7)       
  Hispanic                                                         9291 (8.0)         816 (6.2)                                   785 (6.0)       816 (6.2)       
  Asian/Pacific Islander                                           3215 (2.8)         139 (1.1)                                   190 (1.5)       139 (1.1)       
  Native American                                                  623 (0.5)          50 (0.4)                                    51 (0.4)        50 (0.4)        
  Other                                                            3361 (2.9)         259 (2.0)                                   151 (1.2)       259 (2.0)       
  Unknown                                                          5182 (4.5)         523 (4.0)                                   524 (4.0)       523 (4.0)       
  Patient location, n (%)                                                                             \<.001                                                      .478
  "Central" counties of metro areas of \> = 1 million population   29 511 (25.4)      2878 (21.9)                                 3005 (22.9)     2878 (22.0)     
  "Finge" counties of metro areas of \> = 1 million population     27 020 (23.3)      3131 (23.9)                                 3081 (23.5)     3127 (23.9)     
  Counties in metro areas of 250 000‐999 999 population            23 651 (20.4)      2700 (20.6)                                 2659 (20.3)     2698 (20.6)     
  Counties in metro areas of 50 000‐249 999 population             11 845 (10.2)      1541 (11.8)                                 1467 (11.2)     1540 (11.8)     
  Micropolitan counties                                            13 160 (11.3)      1576 (12.0)                                 1607 (12.3)     1575 (12.0)     
  Non metropolitan or micropolitan counties                        10 587 (9.1)       1256 (9.6)                                  1255 (9.6)      1254 (9.6)      
  NA                                                               419 (0.4)          30 (0.2)                                    28 (0.2)        30 (0.2)        
  Mean household income, n (%)                                                                        0.01                                                        .787
  \$1‐\$42 999                                                     35 151 (30.3)      4088 (31.2)                                 4042 (30.9)     4086 (31.2)     
  \$43 000‐\$53 999                                                30 737 (26.5)      3503 (26.7)                                 3545 (27.1)     3499 (26.7)     
  \$54 000‐\$70 999                                                27 008 (23.2)      3035 (23.1)                                 3072 (23.4)     3033 (23.1)     
  \$71 000 or more                                                 21 112 (18.2)      2278 (17.4)                                 2253 (17.2)     2276 (17.4)     
  Unknown                                                          2185 (1.9)         208 (1.6)                                   190 (1.5)       208 (1.6)       
  Primary payer, n (%)                                                                                \<.001                                                      .067
  Medicare                                                         66 386 (57.1)      7697 (58.7)                                 7606 (58.1)     7690 (58.7)     
  Medicaid                                                         10 513 (9.0)       1484 (11.3)                                 1427 (10.9)     1481 (11.3)     
  Private including HMO (Health maintenance organization)          30 083 (25.9)      3133 (23.9)                                 3194 (24.4)     3133 (23.9)     
  Self‐pay                                                         5249 (4.5)         434 (3.3)                                   525 (4.0)       434 (3.3)       
  No charge                                                        495 (0.4)          37 (0.3)                                    43 (0.3)        37 (0.3)        
  Other                                                            3333 (2.9)         315 (2.4)                                   296 (2.3)       315 (2.4)       
  Unknown                                                          134 (0.1)          12 (0.1)                                    11 (0.1)        12 (0.1)        
  Hospital type, n (%)                                                                                \<.001                                                      .403
  Rural                                                            8805 (7.6)         1185 (9.0)                                  1127 (8.6)      1184 (9.0)      
  Urban nonteaching                                                32 592 (28.0)      3539 (27.0)                                 3591 (27.4)     3537 (27.0)     
  Urban teaching                                                   74 796 (64.4)      8388 (64.0)                                 8384 (64.0)     8381 (64.0)     
  Hospital region, n (%)                                                                              \<.001                                                      .103
  Northeast                                                        20 697 (17.8)      2473 (18.9)                                 2402 (18.3)     2470 (18.9)     
  Midwest                                                          25 997 (22.4)      3267 (24.9)                                 3240 (24.7)     3262 (24.9)     
  South                                                            47 473 (40.9)      5285 (40.3)                                 5228 (39.9)     5283 (40.3)     
  West                                                             22 026 (19.0)      2087 (15.9)                                 2232 (17.0)     2087 (15.9)     
  Hospital bed size, n (%)                                                                            .829                                                        .901
  Small                                                            18 327 (15.8)      2095 (16.0)                                 2067 (15.8)     2094 (16.0)     
  Medium                                                           34 471 (29.7)      3877 (29.6)                                 3880 (29.6)     3873 (29.6)     
  Large                                                            63 395 (54.6)      7140 (54.5)                                 7155 (54.6)     7135 (54.5)     
  Comorbidities, n (%)                                                                                                                                            
  Smoking                                                          26 672 (23.0)      3853 (29.4)     \<.001                      3756 (28.7)     3843 (29.3)     .242
  Hypertension                                                     62 371 (53.7)      7462 (56.9)     \<.001                      7396 (56.4)     7453 (56.9)     .485
  DM                                                               45 243 (38.9)      4768 (36.4)     \<.001                      4813 (36.7)     4764 (36.4)     .538
  Hyperlipidemia                                                   75 135 (64.7)      8910 (68.0)     \<.001                      8907 (68.0)     8901 (67.9)     .947
  Obesity                                                          21 336 (18.4)      2759 (21.0)     \<.001                      2686 (20.5)     2755 (21.0)     .3
  Depression                                                       6756 (5.8)         4214 (32.1)     \<.001                      4103 (31.3)     4204 (32.1)     .184
  History of MI                                                    17 406 (15.0)      2349 (17.9)     \<.001                      2293 (17.5)     2346 (17.9)     .4
  OSA                                                              9788 (8.4)         1532 (11.7)     \<.001                      1535 (11.7)     1526 (11.6)     .878
  CKD                                                              27 578 (23.7)      2834 (21.6)     \<.001                      2824 (21.6)     2834 (21.6)     .893
  History of stroke                                                11 624 (10.0)      1484 (11.3)     \<.001                      1469 (11.2)     1445 (11.0)     .651
  PAD                                                              14 467 (12.5)      1745 (13.3)     .005                        1800 (13.7)     1743 (13.3)     .312
  COPD                                                             19 739 (17.0)      3475 (26.5)     \<.001                      3409 (26.0)     3466 (26.5)     .432

Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; MI, myocardial infarction; NSTEMI, non‐ST elevation myocardial infarction; OSA, obstructive sleep apnea; PAD, peripheral artery disease; STEMI, ST‐segment elevation myocardial infarction; HMO, health maintenance organization.

In the STEMI group, 32 467 patients did not have anxiety and 2770 had anxiety disorders, while for 94 068 patients in the NSTEMI group, 83 726 did not have anxiety and 10 342 had anxiety disorders. Before propensity score matching, like the anxiety group of MI, the STEMI and NSTEMI anxiety groups had more young, female, white patients, and a higher incidence of comorbidities. However, fewer patients had DM (38.3% vs 42.2%, *P* \< .001) and CKD (24.0% vs 28.0%, *P* \< .001) in the NSTEMI with anxiety group vs the without anxiety group, while the DM (29.0% vs 30.6%, *P* = .084) and CKD (12.6% vs 12.7%, *P* = .995) did not differ in the patients in the STEMI group. After propensity score matching, race still maintains a significant difference in the anxiety group and nonanxiety group of the STEMI and NSTEMI respectively (all *P* \< .001) (Table [S2](#clc23358-supitem-0004){ref-type="supplementary-material"} and [S3](#clc23358-supitem-0005){ref-type="supplementary-material"}).

In contrast to previous studies, our study shows that patients with pre‐MI anxiety have a better in‐hospital outcome than those without. In the propensity‐matched group, patients with pre‐MI anxiety are associated with lower in‐hospital mortality (3.0% vs 4.4%, *P* \< .001), cardiac arrest (2.1% vs 2.8%, *P* \< .001), cardiogenic shock (4.9% vs 5.6%, *P* = .007) and VA (6.7% vs 7.9%, *P* \< .001), but a longer LOS (4.7 ± 5.3 vs 4.4 ± 5.6, *P* = .001) (Table [2](#clc23358-tbl-0002){ref-type="table"}). In the group of NSTEMI, after propensity match, we found that the subgroup of pre‐MI anxiety had a lower incidence of in‐hospital death (2.3% vs 3.5%, *P* \< .001), cardiac arrest (1.1% vs 1.5%, *P* = .008), cardiac shock (2.8% vs 3.5%, *P* = .008), and AKI (18.1% vs 19.7%, *P* = .004) (Table [3](#clc23358-tbl-0003){ref-type="table"}). We found no differences, however, in the all primary and secondary outcomes in the STEMI subgroup after propensity score matching, except a longer LOS in the anxiety group (4.7 ± 7.3 vs 4.1 ± 5.4, *P* = .002) (Table [4](#clc23358-tbl-0004){ref-type="table"}).

###### 

In‐hospital outcomes of MI

                              Unmatched cohort      Propensity‐matched cohort                                                        
  --------------------------- --------------------- --------------------------- -------- --------------------- --------------------- --------
  n                           116 193               13 112                               13 102                13 102                
  Outcomes                                                                                                                           
  Death, n (%)                5687 (4.9)            391 (3.0)                   \<.001   571 (4.4)             391 (3.0)             \<.001
  Cardiac arrest, n (%)       3517 (3.0)            269 (2.1)                   \<.001   372 (2.8)             269 (2.1)             \<.001
  Cardiogenic shock, n (%)    7190 (6.2)            638 (4.9)                   \<.001   736 (5.6)             638 (4.9)             .007
  VA, n (%)                   9833 (8.5)            882 (6.7)                   \<.001   1041 (7.9)            881 (6.7)             \<.001
  Acute CHF, n (%)            22 112 (19.0)         2526 (19.3)                 .525     2457 (18.8)           2523 (19.3)           .306
  AKI, n (%)                  22 204 (19.1)         2299 (17.5)                 \<.001   2282 (17.4)           2298 (17.5)           .807
  ARF, n (%)                  12 908 (11.1)         1609 (12.3)                 \<.001   1514 (11.6)           1607 (12.3)           .079
  LOS, (mean \[SD\])          4.4 (5.5)             4.7 (5.3)                   \<.001   4.4 (5.6)             4.7 (5.3)             .001
  Total cost, (mean \[SD\])   21 438.6 (23 146.7)   20 760.3 (22 320.8)         .002     20 695.9 (22 825.6)   20 763.3 (22 327.1)   .811

Abbreviations: AKI, acute kidney injury; ARF, acute respiratory failure; CHF, congestive heart failure; LOS, length of stay; MI, myocardial infarction; SD, standard deviation.

###### 

In‐hospital outcomes of NSTEMI

                              Unmatched cohort      Propensity‐matched cohort                                                        
  --------------------------- --------------------- --------------------------- -------- --------------------- --------------------- --------
  n                           83 726                10 342                               10 340                10 340                
  Outcomes                                                                                                                           
  Death, n (%)                3010 (3.6)            235 (2.3)                   \<.001   367 (3.5)             235 (2.3)              \<.001
  Cardiac arrest, n (%)       1485 (1.8)            111 (1.1)                   \<.001   155 (1.5)             111 (1.1)               .008
  Cardiogenic shock, n (%)    2974 (3.6)            292 (2.8)                   \<.001   360 (3.5)             292 (2.8)               .008
  VA, n (%)                   4441 (5.3)            452 (4.4)                   \<.001   503 (4.9)             452 (4.4)               .098
  Acute CHF, n (%)            17 804 (21.3)         2107 (20.4)                 .037     2206 (21.3)           2107 (20.4)             .093
  AKI, n (%)                  17 102 (20.4)         1869 (18.1)                 \<.001   2034 (19.7)           1869 (18.1)             .004
  ARF, n (%)                  8951 (10.7)           1245 (12.0)                 \<.001   1250 (12.1)           1245 (12.0)             .932
  LOS, (mean \[SD\])          4.6 (5.4)             4.7 (4.6)                   .201     4.6 (5.2)             4.7 (4.6)               .431
  Total cost, (mean \[SD\])   19 922.2 (21 528.5)   19 348.8 (18 256.4)         .01      19 550.9 (19 836.5)   19 350.6 (18 257.8)     .455

Abbreviations: AKI, acute kidney injury; ARF, acute respiratory failure; CHF, congestive heart failure; LOS, length of stay; NSTEMI, non‐ST elevation myocardial infarction; SD, standard deviation.

###### 

In‐hospital outcomes of STEMI

                             Unmatched cohort      Propensity‐matched cohort                                                        
  -------------------------- --------------------- --------------------------- -------- --------------------- --------------------- -------
  n                          32 467                2770                                 2768                  2768                  
  Outcomes                                                                                                                          
  Death, n (%)               2677 (8.2)            156 (5.6)                   \<.001   191 (6.9)             156 (5.6)             .059
  Cardiac arrest, n (%)      2032 (6.3)            158 (5.7)                   .263     155 (5.6)             158 (5.7)             .907
  Cardiogenic shock, n (%)   4216 (13.0)           346 (12.5)                  .475     320 (11.6)            346 (12.5)            .302
  VA, n (%)                  5392 (16.6)           430 (15.5)                  .148     419 (15.1)            430 (15.5)            0.709
  Acute CHF, n (%)           4308 (13.3)           419 (15.1)                  .006     376 (13.6)            419 (15.1)            .107
  AKI, n (%)                 5102 (15.7)           430 (15.5)                  .812     439 (15.9)            430 (15.5)            .768
  ARF, n (%)                 3957 (12.2)           364 (13.1)                  .151     323 (11.7)            364 (13.2)            .103
  LOS (mean \[SD\])          4.1 (5.5)             4.7 (7.3)                   \<.001   4.1 (5.4)             4.7 (7.3)             .002
  Total cost (mean \[SD\])   25 318.6 (26 454.5)   25 996.5 (32 795.6)         .208     25 065.3 (26 233.7)   25 998.9 (32 807.4)   .245

Abbreviations: AKI, acute kidney injury; ARF, acute respiratory failure; CHF, congestive heart failure; LOS, length of stay; SD, standard deviation; STEMI, ST‐segment elevation myocardial infarction.

7. DISCUSSION {#clc23358-sec-0012}
=============

To our knowledge, this study is the first to investigate the effect of preexisting anxiety disorders on in‐patient outcomes of subgroups of MI patients. Unlike previous studies, by using the national representative hospitalization database, we primarily observed that preexisting anxiety was associated with decreased in‐hospital mortality, a lower incidence of cardiac arrest, cardiogenic shock, and VA in MI inpatients. Interestingly, the same effects in mortality, cardiac arrest, and cardiogenic shock were found in patients with anxiety in the NSTEMI subgroup but not in STEMI subgroup.

It is well established that preexisting anxiety is associated with worse long‐term outcomes in MI patients.[15](#clc23358-bib-0015){ref-type="ref"}, [16](#clc23358-bib-0016){ref-type="ref"}, [17](#clc23358-bib-0017){ref-type="ref"} Several hypotheses have been proposed to explain the negative impacts of preexisting anxiety disorders on the long‐term outcomes in patients with MI, such as the change of biological behavior: heavy drinking,[21](#clc23358-bib-0021){ref-type="ref"} nicotine dependence,[22](#clc23358-bib-0022){ref-type="ref"} and lack of exercise.[23](#clc23358-bib-0023){ref-type="ref"} Another hypothesis is that anxiety can escalate the inflammatory response by activating inflammatory markers such as C‐reactive protein, interleukin‐6, and homocysteine,[24](#clc23358-bib-0024){ref-type="ref"}, [25](#clc23358-bib-0025){ref-type="ref"} which may in turn lead to the formation of the coronary thrombosis. In addition, studies showed that anxiety can interrupt the balance of autonomic nervous system by reducing the vagal tone, making a higher incidence of ventricular fibrillation and tachycardia.[26](#clc23358-bib-0026){ref-type="ref"}, [27](#clc23358-bib-0027){ref-type="ref"}

Mood disorders including anxiety and depression mainly affect the body by activating the sympathetic nervous system and result in a high level of catecholamine.[28](#clc23358-bib-0028){ref-type="ref"} Fioranelli et al found that a high level of catecholamine increases the cortisol, which also leads to the increased risk of ischemic heart diseases.[29](#clc23358-bib-0029){ref-type="ref"} Interestingly, other studies suggested that catecholamine may have a protective effect of MI in acute setting. Abete et al found that elevated levels of norepinephrine in mice can reduce the area of myocardial damage during ischemia‐reperfusion.[30](#clc23358-bib-0030){ref-type="ref"} This phenomenon might be explained by the ischemic preconditioning (IPC), which is an adaptational response of brief episodes of ischemia where reperfusion serves to protect against subsequent prolonged ischemia‐reperfusion injury. Although the mechanism of IPC remains unclear, several studies have shown that the protective effects are mediated by the elevation of plasma catecholamine during brief episodes of ischemia and reperfusion.[31](#clc23358-bib-0031){ref-type="ref"}, [32](#clc23358-bib-0032){ref-type="ref"} Anxiety disorders can similarly lead to increased plasma catecholamine and can possibly mimic the process of myocardial preconditioning, which resulted in less ischemia and reperfusion injury in acute MI.

Moreover, anxiety disorders and cardiovascular diseases present with similar symptoms such as chest pain, palpitation, and dyspnea. Patients with anxiety might seek medical attention promptly and more frequently, which might lead to early diagnosis and treatment compared to patients without a preexisting diagnosis of anxiety.

Preexisting anxiety was associated with better in‐hospital outcomes in NSTEMI but not in STEMI. By definition, STEMI is a transmural myocardial infarction (full‐thickness myocardial necrosis) and is most often caused by complete and persistent occlusion of a coronary artery by thrombus, while NSTEMI is a non‐full‐wall myocardial necrosis and usually due to a decrease in blood supply via partial occlusion of the affected coronary artery.[33](#clc23358-bib-0033){ref-type="ref"} Traditionally, patients with STEMI have a substantially higher in‐hospital mortality than those with NSTEMI.[1](#clc23358-bib-0001){ref-type="ref"} The protective effects of anxiety disorders in STEMI could be less significant than in NSTEMI because the more severe myocardial necrosis in STEMI, the less involvement there is of reperfusion injury (which might be alleviated by preexisting anxiety disorders) given the underlying etiology of complete occlusion of the coronary artery in STEMI.

Our study has several limitations. First, because of its retrospective observational design, our study can help establish associations, but not causality. Further mechanistic study is warranted to verify these findings. Second, the absence of data on whether patients received antianxiety therapy in the data set prevented us from examining antianxiety therapy‐related effects. Third, we were unable to analyze the effects of other cardiovascular drug treatments, especially the β‐adrenergic receptor blockers, which antagonize the sympathetic nervous system. Fourth, a previous study showed that the sensitivity and specificity of the ICD‐10‐CM code for identifying MI was about 61.5% and 99.4%, respectively.[34](#clc23358-bib-0034){ref-type="ref"} Misclassification may be a source of bias. Finally, because of the limitations of the database, we were unable to include other possible residual confounding factors, such as access to healthcare, diet/lifestyle, and detailed socioeconomic information (which were not available in NIS and may be potential explanations for the better outcomes in NSTEMI), into our analysis.

8. CONCLUSIONS {#clc23358-sec-0013}
==============

In summary, although previous studies have found that anxiety is associated with a negative effect on the outcomes of MI, we found that preexisting anxiety was associated with positive short‐term prognosis of MI patients in terms of decreased in‐hospital mortality, cardiac arrest, cardiogenic shock, and VA. On the other hand, anxiety has different effects on the subtypes of MI. Preexisting anxiety plays a beneficial role in the short‐term prognosis of patients with NSTEMI with a lower incidence of in‐hospital mortality, cardiac arrest, and cardiogenic shock, but no material effects on inpatient outcomes for the patients in the STEMI group.

CONFLICT OF INTEREST {#clc23358-sec-0014}
====================

The authors declare no potential conflict of interest.

Supporting information
======================

###### 

**Figure S1**. Flow chart of the selection process for the final patient sample in the STEMI subgroup used in this study. Inclusion criteria were applied to the National Inpatient Sample 2016 database. All eligible patients were matched 1:1 based on propensity scoring to generate the anxiety vs nonanxiety comparison cohorts. ICD‐10‐CM code: Tenth Revision, Clinical Modification Code. STEMI: ST‐segment elevation myocardial infarction.
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**Figure S2**. Flow chart of the selection process for the final patient sample in the NSTEMI subgroup used in this study. Inclusion criteria were applied to the National Inpatient Sample 2016 database. All eligible patients were matched 1:1 based on propensity scoring to generate the anxiety vs nonanxiety comparison cohorts. ICD‐10‐CM code: Tenth Revision, Clinical Modification Code. NSTEMI: non‐ST elevation myocardial infarction.
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**Table S1** International Classification of Disease, Version 10 (ICD‐10) Codes Used for Co‐Morbidity and Outcomes Identification
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**Table S2** Baseline Characteristics of NSTEMI
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**Table S3** Baseline Characteristics of STEMI
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